Eliyahu Sharon Kalif - 28 Feb 2023 Form 4 Insider Report for TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)

Role
EVP, Chief Financial Officer
Signature
/s/ Dov Bergwerk as attorney-in-fact for Eliyahu Sharon Kalif
Issuer symbol
TEVA
Transactions as of
28 Feb 2023
Net transactions value
$0
Form type
4
Filing time
02 Mar 2023, 06:36:02 UTC
Previous filing
15 Feb 2023
Next filing
07 Mar 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TEVA Ordinary Shares Options Exercise +18,430 +115% 34,435 28 Feb 2023 Direct F1, F2
transaction TEVA Ordinary Shares Options Exercise +44,953 +131% 79,388 28 Feb 2023 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TEVA Restricted Share Units Options Exercise $0 -18,430 -50% $0.000000 18,430 28 Feb 2023 Ordinary Shares 18,430 Direct F1, F2, F3
transaction TEVA Restricted Share Units Options Exercise $0 -44,953 -100% $0.000000* 0 28 Feb 2023 Ordinary Shares 44,953 Direct F1, F2, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
F2 Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
F3 Restricted share units were granted on February 28, 2020 with 18,430 vested on each of February 28, 2021, February 28, 2022, February 28, 2023 and 18,430 vesting on February 28, 2024.
F4 Restricted share units were granted on February 7, 2023 pursuant to the satisfaction of performance criteria and vested on February 28, 2023.